About

Ascenta Capital describes itself as a venture firm that invests in biotechnology companies developing multiple therapeutic medicines from a common platform. The firm focuses on early-stage biotech companies — typically those advancing through Phase 1 and Phase 2 clinical trials — and works with them to support their clinical, regulatory, manufacturing, and capital strategy needs. Ascenta Capital provides concentrated investment and strategic guidance, partnering closely with management teams to help translate scientific research into therapies for patients. The firm pursues a portfolio-construction approach that balances risk by backing multi-asset biotech platforms rather than single-asset startups.

Position in the VCSift Database

  • 33,888 investors in VCSift focus on the fintech sector.
  • 10,621 investors are based in New York, New York, United States.

Data sourced from 410,343 investor profiles. Updated July 2026.

Investment Focus

Sectors
fintech

Contact Information

em••••@example.com
linkedin.com/in/••••••••

Unlock contact details with a VCSift subscription

Unlock Contact

Already subscribed? Log in

Find more investors like Ascenta

Search Investors